GlobalData on MSN3d
Context doses first subject in Phase I cancer trial of CTIM-76
Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting claudin 6 (CLDN6)-positive ...
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving ...
Stocktwits on MSN10d
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too
Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage ...
Context doses first patient in Phase 1 clinical trial evaluating CTIM-76
Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or ...
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Mr. Pasternak brings decades of global pharmaceutical leadership experienceTransition further highlights transformation of the Board to lead ...
Context Therapeutics (NASDAQ:CNTX) Upgraded at Citizens Jmp
Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of “Buy” by Analysts
Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Six research ...
Morningstar4d
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...